Negative and cognitive symptoms of schizophrenia — primary vs secondary and treatment honesty (MEQ)

(i) Primary vs secondary contributors. This is not yet established pure primary deficit syndrome. Secondary drivers present: EPS/parkinsonism (rigidity, shuffle) on high-dose risperidone with anticholinergic cover; sedating polypharmacy (quetiapine 300 mg night plus risperidone); possible depression (low mood, passive death wishes); residual positive symptoms (voices) that can drive withdrawal; understimulation and long unemployment. Primary negatives may coexist after secondary causes are treated, but labelling "untreatable" now is premature.^[2][7]

(ii) Assessment. History: onset of negatives vs medication changes; premorbid function; typical day; pleasure/motivation; substances; medical. MSE for affect range, alogia, self-care, insight. Risk: suicide (explicit), self-neglect, vulnerability, capacity. Scales: SANS domains conceptually / PANSS negative items; note two-factor structure (expression vs avolition–apathy). Cognition: MATRICS-style domains (processing speed, attention, working memory, learning, reasoning, social cognition); consider formal testing/cognitive remediation referral. Collateral essential.^[1][2][8]

(iii) Stepwise plan. (1) Treat secondary causes: reduce EPS (dose reduction or switch; review benztropine necessity — anticholinergics can worsen cognition); stop unnecessary sedation; treat depression if confirmed; optimise residual positives. (2) Measurement-based follow-up of negatives and function. (3) Cognitive remediation with link to supported employment/IPS and structured activity (Wykes meta-analytic support). (4) Family psychoeducation, skills training, housing support per RANZCP psychosocial framing. (5) Realistic goals; Fusar-Poli reminds overall drug effects on negatives are often small.^[3][6][7][8]

(iv) Cariprazine and clozapine nuance. Cariprazine: Németh RCT showed benefit versus risperidone in a predominant negative symptoms population — cite phenotype carefully; not a panacea for all deficit syndromes; confirm local indication/label and titrate per product information after secondary causes addressed.^[4] Clozapine: Kane superiority is for TRS after adequate failed trials with adherence — not automatic for isolated primary negatives without TRRIP-style resistance; do not claim clozapine as a proven primary-negative cure; if TRS criteria are later met, offer with full monitoring pathway.^[5][7]

(v) Pitfalls. Calling secondary EPS "primary"; ignoring suicide under flat affect; stacking antipsychotics for avolition; overclaiming cariprazine beyond trial design; starting clozapine without TRS logic; omitting cognitive remediation and employment; inventing Mental Health Act section numbers.^[2][3][4][5]